Top-Rated StocksTop-RatedNASDAQ:VRDN Viridian Therapeutics (VRDN) Stock Forecast, Price & News $23.73 -0.08 (-0.34%) (As of 05/26/2023 ET) Add Compare Share Share Today's Range$23.34▼$24.0250-Day Range$22.57▼$29.6752-Week Range$9.84▼$39.00Volume272,021 shsAverage Volume720,342 shsMarket Capitalization$1.02 billionP/E RatioN/ADividend YieldN/APrice Target$45.08 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Viridian Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside90.0% Upside$45.08 Price TargetShort InterestBearish10.11% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.80Based on 4 Articles This WeekInsider TradingSelling Shares$871,257 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($5.25) to ($4.57) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.23 out of 5 starsMedical Sector395th out of 1,012 stocksMedical Laboratories Industry9th out of 24 stocks 4.5 Analyst's Opinion Consensus RatingViridian Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 11 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $45.08, Viridian Therapeutics has a forecasted upside of 90.0% from its current price of $23.73.Amount of Analyst CoverageViridian Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.11% of the outstanding shares of Viridian Therapeutics have been sold short.Short Interest Ratio / Days to CoverViridian Therapeutics has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in Viridian Therapeutics has recently increased by 24.93%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldViridian Therapeutics does not currently pay a dividend.Dividend GrowthViridian Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VRDN. Previous Next 2.7 News and Social Media Coverage News SentimentViridian Therapeutics has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Viridian Therapeutics this week, compared to 3 articles on an average week.MarketBeat Follows2 people have added Viridian Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Viridian Therapeutics insiders have sold 232.79% more of their company's stock than they have bought. Specifically, they have bought $261,805.00 in company stock and sold $871,257.00 in company stock.Percentage Held by InsidersOnly 4.48% of the stock of Viridian Therapeutics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Viridian Therapeutics are expected to grow in the coming year, from ($5.25) to ($4.57) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Viridian Therapeutics is -5.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Viridian Therapeutics is -5.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioViridian Therapeutics has a P/B Ratio of 4.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Viridian Therapeutics (NASDAQ:VRDN) StockViridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.Read More Receive VRDN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Viridian Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address VRDN Stock News HeadlinesMay 21, 2023 | msn.comViridian Therapeutics Has PromiseMay 18, 2023 | americanbankingnews.comViridian Therapeutics (NASDAQ:VRDN) Sees Strong Trading VolumeMay 28, 2023 | Stocks To Trade (Ad)3 Free Stock Picks per DayUsing our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 18, 2023 | americanbankingnews.comAnalysts Set Viridian Therapeutics, Inc. (NASDAQ:VRDN) PT at $45.08May 14, 2023 | americanbankingnews.comViridian Therapeutics, Inc. to Post Q2 2023 Earnings of ($1.81) Per Share, SVB Leerink Forecasts (NASDAQ:VRDN)May 13, 2023 | americanbankingnews.comViridian Therapeutics (NASDAQ:VRDN) Price Target Cut to $44.00 by Analysts at JMP SecuritiesMay 12, 2023 | msn.comOppenheimer Maintains Viridian Therapeutics (VRDN) Outperform RecommendationMay 12, 2023 | americanbankingnews.comResearch Analysts Issue Forecasts for Viridian Therapeutics, Inc.'s Q2 2023 Earnings (NASDAQ:VRDN)May 28, 2023 | Legacy Research (Affiliate) (Ad)Bear market expert makes new predictionNobody believed Larry Benedict's prediction in February 2020. The DOW plunged 3.5%, and he told CNBC, "It seems like there's much more to come." Within a month, the market plummeted 34%. Then, nobody believed Larry at the start of last year, either. He predicted that "all the indexes will be negative for the year," with the Nasdaq leading the way. Once again, he was spot-on.May 12, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for Viridian Therapeutics, Inc. Increased by B. Riley (NASDAQ:VRDN)May 12, 2023 | americanbankingnews.comAnalysts Issue Forecasts for Viridian Therapeutics, Inc.'s Q2 2023 Earnings (NASDAQ:VRDN)May 12, 2023 | msn.comCredit Suisse Reiterates Viridian Therapeutics (VRDN) Outperform RecommendationMay 11, 2023 | americanbankingnews.comBrokers Issue Forecasts for Viridian Therapeutics, Inc.'s Q2 2023 Earnings (NASDAQ:VRDN)May 11, 2023 | americanbankingnews.comViridian Therapeutics (NASDAQ:VRDN) Price Target Lowered to $40.00 at OppenheimerMay 10, 2023 | markets.businessinsider.comAnalyst Ratings for Viridian TherapeuticsMay 10, 2023 | msn.comWedbush Maintains Viridian Therapeutics (VRDN) Outperform RecommendationMay 10, 2023 | msn.comHC Wainwright & Co. Reiterates Viridian Therapeutics (VRDN) Buy RecommendationMay 10, 2023 | markets.businessinsider.comViridian Therapeutics (VRDN) Gets a Buy from Credit SuisseMay 10, 2023 | markets.businessinsider.comWedbush Keeps Their Buy Rating on Viridian Therapeutics (VRDN)May 10, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Viridian Therapeutics (VRDN), Neuronetics (STIM)May 9, 2023 | finance.yahoo.comViridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Misses Revenue EstimatesMay 9, 2023 | msn.comRecap: Viridian Therapeutics Q1 EarningsMay 9, 2023 | finance.yahoo.comViridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate UpdateMay 8, 2023 | msn.comEarnings Outlook For Viridian TherapeuticsMay 8, 2023 | msn.comViridian Therapeutics partners with Enable Injections for wearable drug delivery system developmentMay 8, 2023 | finance.yahoo.comViridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable InjectionsMay 7, 2023 | americanbankingnews.comViridian Therapeutics (VRDN) Scheduled to Post Quarterly Earnings on TuesdaySee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive VRDN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Viridian Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address VRDN Company Calendar Last Earnings5/09/2023Today5/28/2023Next Earnings (Estimated)8/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VRDN CUSIPN/A CIK1590750 Webwww.viridiantherapeutics.com Phone(617) 272-4600Fax760-537-4101Employees50Year FoundedN/APrice Target and Rating Average Stock Price Forecast$45.08 High Stock Price Forecast$51.00 Low Stock Price Forecast$40.00 Forecasted Upside/Downside+90.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($4.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-129,870,000.00 Net Margins-10,419.10% Pretax Margin-10,419.10% Return on Equity-89.08% Return on Assets-48.13% Debt Debt-to-Equity Ratio0.02 Current Ratio12.93 Quick Ratio12.93 Sales & Book Value Annual Sales$1.77 million Price / Sales578.23 Cash FlowN/A Price / Cash FlowN/A Book Value$5.00 per share Price / Book4.75Miscellaneous Outstanding Shares43,130,000Free Float41,200,000Market Cap$1.02 billion OptionableNot Optionable Beta0.95 Key ExecutivesScott D. MyersPresident, Chief Executive Officer & DirectorKristian Franz HumerChief Financial, Accounting & Business OfficerVahe BedianChief ScientistBarrett KatzChief Medical OfficerLara MeisnerSecretary, Senior Vice President & General CounselKey CompetitorsFulgent GeneticsNASDAQ:FLGTProgenityNASDAQ:PROGCastle BiosciencesNASDAQ:CSTLRadNetNASDAQ:RDNTCareDxNASDAQ:CDNAView All CompetitorsInsiders & InstitutionsJPMorgan Chase & Co.Sold 122,982 shares on 5/18/2023Ownership: 0.114%New York State Common Retirement FundSold 2,892 shares on 5/18/2023Ownership: 0.046%Geode Capital Management LLCBought 65,127 shares on 5/16/2023Ownership: 1.800%Susquehanna International Group LLPBought 15,600 shares on 5/16/2023Ownership: 0.000%AQR Capital Management LLCBought 2,968 shares on 5/16/2023Ownership: 0.024%View All Insider TransactionsView All Institutional Transactions VRDN Stock - Frequently Asked Questions Should I buy or sell Viridian Therapeutics stock right now? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viridian Therapeutics in the last year. There are currently 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VRDN shares. View VRDN analyst ratings or view top-rated stocks. What is Viridian Therapeutics' stock price forecast for 2023? 11 Wall Street analysts have issued 12-month price targets for Viridian Therapeutics' shares. Their VRDN share price forecasts range from $40.00 to $51.00. On average, they predict the company's share price to reach $45.08 in the next year. This suggests a possible upside of 90.0% from the stock's current price. View analysts price targets for VRDN or view top-rated stocks among Wall Street analysts. How have VRDN shares performed in 2023? Viridian Therapeutics' stock was trading at $29.21 at the beginning of the year. Since then, VRDN stock has decreased by 18.8% and is now trading at $23.73. View the best growth stocks for 2023 here. Are investors shorting Viridian Therapeutics? Viridian Therapeutics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 4,360,000 shares, an increase of 24.9% from the April 30th total of 3,490,000 shares. Based on an average daily volume of 604,000 shares, the days-to-cover ratio is currently 7.2 days. View Viridian Therapeutics' Short Interest. When is Viridian Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023. View our VRDN earnings forecast. How were Viridian Therapeutics' earnings last quarter? Viridian Therapeutics, Inc. (NASDAQ:VRDN) issued its earnings results on Tuesday, May, 9th. The company reported ($1.61) EPS for the quarter, missing analysts' consensus estimates of ($1.00) by $0.61. The business earned $0.10 million during the quarter, compared to analyst estimates of $0.10 million. Viridian Therapeutics had a negative net margin of 10,419.10% and a negative trailing twelve-month return on equity of 89.08%. The company's revenue for the quarter was down 54.6% compared to the same quarter last year. During the same period last year, the firm posted ($0.98) earnings per share. What ETFs hold Viridian Therapeutics' stock? ETFs with the largest weight of Viridian Therapeutics (NASDAQ:VRDN) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco DWA SmallCap Momentum ETF (DWAS), Principal Healthcare Innovators ETF (BTEC), iShares Micro-Cap ETF (IWC).BlackRock Future Health ETF (BMED) and What is Viridian Therapeutics' stock symbol? Viridian Therapeutics trades on the NASDAQ under the ticker symbol "VRDN." Who are Viridian Therapeutics' major shareholders? Viridian Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (6.43%), State Street Corp (5.57%), Commodore Capital LP (5.08%), Perceptive Advisors LLC (4.03%), Pictet Asset Management SA (2.42%) and Logos Global Management LP (2.20%). Insiders that own company stock include Barrett Katz, Fairmount Funds Management Llc, Jonathan Violin, Lara Meisner, Life Sciences Public F Frazier and Scott Dunseth Myers. View institutional ownership trends. How do I buy shares of Viridian Therapeutics? Shares of VRDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Viridian Therapeutics' stock price today? One share of VRDN stock can currently be purchased for approximately $23.73. How much money does Viridian Therapeutics make? Viridian Therapeutics (NASDAQ:VRDN) has a market capitalization of $1.02 billion and generates $1.77 million in revenue each year. The company earns $-129,870,000.00 in net income (profit) each year or ($4.66) on an earnings per share basis. How can I contact Viridian Therapeutics? Viridian Therapeutics' mailing address is 6200 LOOKOUT ROAD, BOULDER CO, 80301. The official website for the company is www.viridiantherapeutics.com. The company can be reached via phone at (617) 272-4600, via email at daniel@lifesciadvisors.com, or via fax at 760-537-4101. This page (NASDAQ:VRDN) was last updated on 5/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viridian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.